Lise Aagaard1, Ebba Holme Hansen. 1. Faculty of Health Sciences, Institute of Public Health, University of Southern Denmark, J.B. Winsløws Vej 19, 5000, Odense C, Denmark, laagaard@health.sdu.dk.
Abstract
BACKGROUND: Respiratory medications are frequently prescribed for use in children. Several studies have reported information on the safety of asthma medications in clinical studies in adults, but information about safety in children is scarce. OBJECTIVE: To review published clinical trials on the occurrence and characteristics of adverse drug reactions (ADRs) in children, reported for asthma medications licensed for paediatric use. METHODS: We systematically reviewed the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. PubMed, Embase, Cochrane Library, PsycINFO, IPA, and CINAHLs databases were searched from origin until July 2013 for studies reporting ADRs for beta2-receptor agonists, inhaled corticosteroids, leukotriene receptor antagonists and combination products in children from birth to age 17. Information on ADR reporting rates, age and gender, type and seriousness of ADRs, design, setting, observation period, type of assessors, and funding sources was extracted from the articles. RESULTS: Literature searches resulted in 162 potential relevant articles. However only 12 of these studies were included in this review as they reported information about ADR rates from use of salmeterol, formoterol, fluticasone, montelukast, zafirlukast and budesonide/formoterol in children. The total population was approximately 3,000 children; the majority was 6- to 11-year-olds and two thirds of these were boys. The observation period varied from 1 to 22 months. The most frequently reported ADRs were exacerbation of asthma, respiratory tract infection, cough, fever and headache. Only few ADRs were rated as being serious, however a number of children dropped out of the clinical trials due to serious ADRs, and, therefore, the real number of serious ADRs is probably higher. CONCLUSIONS: Few clinical trials reporting ADRs from use of asthma medications in children were identified in the literature. These studies reported only a few types of ADRs, the majority being non-serious.
BACKGROUND: Respiratory medications are frequently prescribed for use in children. Several studies have reported information on the safety of asthma medications in clinical studies in adults, but information about safety in children is scarce. OBJECTIVE: To review published clinical trials on the occurrence and characteristics of adverse drug reactions (ADRs) in children, reported for asthma medications licensed for paediatric use. METHODS: We systematically reviewed the literature following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement guidelines. PubMed, Embase, Cochrane Library, PsycINFO, IPA, and CINAHLs databases were searched from origin until July 2013 for studies reporting ADRs for beta2-receptor agonists, inhaled corticosteroids, leukotriene receptor antagonists and combination products in children from birth to age 17. Information on ADR reporting rates, age and gender, type and seriousness of ADRs, design, setting, observation period, type of assessors, and funding sources was extracted from the articles. RESULTS: Literature searches resulted in 162 potential relevant articles. However only 12 of these studies were included in this review as they reported information about ADR rates from use of salmeterol, formoterol, fluticasone, montelukast, zafirlukast and budesonide/formoterol in children. The total population was approximately 3,000 children; the majority was 6- to 11-year-olds and two thirds of these were boys. The observation period varied from 1 to 22 months. The most frequently reported ADRs were exacerbation of asthma, respiratory tract infection, cough, fever and headache. Only few ADRs were rated as being serious, however a number of children dropped out of the clinical trials due to serious ADRs, and, therefore, the real number of serious ADRs is probably higher. CONCLUSIONS: Few clinical trials reporting ADRs from use of asthma medications in children were identified in the literature. These studies reported only a few types of ADRs, the majority being non-serious.
Authors: Eileen M Duggan; Jennifer Sturley; Anthony P Fitzgerald; Ivan J Perry; Jonathan O'B Hourihane Journal: Pediatr Allergy Immunol Date: 2012-03-22 Impact factor: 6.377
Authors: T W de Vries; J J de Langen-Wouterse; E van Puijenbroek; E J Duiverman; L T W de Jong-Van den Berg Journal: Eur J Clin Pharmacol Date: 2006-04-01 Impact factor: 2.953
Authors: Nan Chiang; Ian R Riley; Jesmond Dalli; Ana R Rodriguez; Bernd W Spur; Charles N Serhan Journal: FASEB J Date: 2018-02-28 Impact factor: 5.191
Authors: Giuseppe Fabio Parisi; Sara Manti; Maria Papale; Alessandro Giallongo; Cristiana Indolfi; Michele Miraglia Del Giudice; Carmelo Salpietro; Amelia Licari; Gian Luigi Marseglia; Salvatore Leonardi Journal: Acta Biomed Date: 2022-05-11
Authors: James S Leung; David W Johnson; Arissa J Sperou; Jennifer Crotts; Erik Saude; Lisa Hartling; Antonia Stang Journal: PLoS One Date: 2017-08-09 Impact factor: 3.240